Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
Nature
|
August 17, 2012
Recurrent R-spondin fusions in colon cancer
Somasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies
Matthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Cancer Research
|
March 5, 2009
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection
Andrew G Polson, Jill Calemine-Fenaux, Pamela Chan, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
Romain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Research Square
|
December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Brandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Breast Cancer Research : BCR
|
April 24, 2015
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
Christy C Ong, Sarah Gierke, Cameron Pitt, et al.
Cancer Cell
|
November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Habib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Nature
|
February 5, 2025
IL-27 elicits a cytotoxic CD8<sup>+</sup> T cell program to enforce tumour control
Béatrice Bréart, Katherine Williams, Stellanie Krimm, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
Nature
|
August 17, 2012
Recurrent R-spondin fusions in colon cancer
Somasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 21, 2013
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies
Matthew J Brauer, Guanglei Zhuang, Maike Schmidt, et al.
Cancer Research
|
March 5, 2009
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection
Andrew G Polson, Jill Calemine-Fenaux, Pamela Chan, et al.
Journal for Immunotherapy of Cancer
|
April 8, 2021
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
Romain Banchereau, Avantika S Chitre, Alexis Scherl, et al.
Research Square
|
December 23, 2024
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Brandon M Lehrich, Evan R Delgado, Tyler M Yasaka, et al.
Breast Cancer Research : BCR
|
April 24, 2015
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents
Christy C Ong, Sarah Gierke, Cameron Pitt, et al.
Cancer Cell
|
November 22, 2024
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Habib Hamidi, Yasin Senbabaoglu, Niha Beig, et al.
Nature
|
February 5, 2025
IL-27 elicits a cytotoxic CD8<sup>+</sup> T cell program to enforce tumour control
Béatrice Bréart, Katherine Williams, Stellanie Krimm, et al.
Page
of 15